Today, the Senate passed a Continuing Resolution (CR) that includes a 57% cut to the Congressionally Directed Medical Research Program (CDMRP). While the CR may keep the government running in the short term, it brings with it concerning implications for Duchenne and Becker muscular dystrophy research.

The CDMRP, specifically the Peer-Reviewed Medical Research Program (PRMRP), has been a critical source of funding for Duchenne and Becker research, supporting groundbreaking studies and accelerating therapeutic development. This significant cut of the CDMRP program will slow progress at a time when scientific advancements are finally opening new doors for therapies. Reduced funding means fewer grants awarded, fewer clinical trials, and a slowdown in the development of potentially life-changing therapies.

For families affected by Duchenne and Becker, this is not just a budget issue. Every delay in research and development means lost time for those who cannot afford to wait. The Duchenne and Becker community has fought tirelessly for federal support, and these cuts represent a step backward in the mission to find effective therapies and, ultimately, end Duchenne.

PPMD will continue to keep the community updated as we learn more about the exact details and implications of this budget cut. Now more than ever, we must advocate for continued investment in Duchenne and Becker research. We urge lawmakers to recognize the critical importance of the CDMRP and ensure that Duchenne and Becker remain a priority in federal funding decisions. Our community is strong, and together, we will continue to push for policies that support the progress we so desperately need.

Please reach out to Lauren Stanford, PPMD’s Senior Director of Advocacy, with any questions.